Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Statin drugs exploit a metabolic vulnerability in high-risk multiple myeloma
EF 2019-20
Résumé
"Multiple myeloma (MM) is a cancer of the antibody-producing plasma cells, a type of white blood cell that is an essential component of the immune system. Nearly 3,000 Canadians are diagnosed with MM every year, with a median survival rate of approximately three years despite current standard-of-care treatments. Statins are a family of cholesterol-lowering drugs, produced off-patent at a low cost and with an established record of safety and efficacy. Recently, certain subtypes of MM have been shown to be selectively killed by treatment with statins, though the mechanism of this response and the genetic factors that cause one patient to respond to statins while another does not remain unclear. This study will reveal the molecular determinants of statin-induced cell death, a quality that may be screened for or amplified in patients to promote the efficacy of statin treatment. Statins will be tested in conjunction with the current standard-of-care therapy, providing pre-clinical evidence for the use of statins in patients. Ultimately, this will advance the use of statins to the oncology clinic, moving one step closer to employing a cheap, safe, and effective family of cholesterol-lowering drugs to treat aggressive forms of cancer."
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
428974
Name
MacDonald Kate
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Statin drugs exploit a metabolic vulnerability in high-risk multiple myeloma
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer; Combination Therapy; Crispr/Cas9; Improved Patient Outcome; Metabolomics; Mevalonate Metabolism; Mouse Xenograft Model; Multiple Myeloma; Statin Family Of Drugs; Tumour Metabolism
Abstract
"Multiple myeloma (MM) is a cancer of the antibody-producing plasma cells, a type of white blood cell that is an essential component of the immune system. Nearly 3,000 Canadians are diagnosed with MM every year, with a median survival rate of approximately three years despite current standard-of-care treatments. Statins are a family of cholesterol-lowering drugs, produced off-patent at a low cost and with an established record of safety and efficacy. Recently, certain subtypes of MM have been shown to be selectively killed by treatment with statins, though the mechanism of this response and the genetic factors that cause one patient to respond to statins while another does not remain unclear. This study will reveal the molecular determinants of statin-induced cell death, a quality that may be screened for or amplified in patients to promote the efficacy of statin treatment. Statins will be tested in conjunction with the current standard-of-care therapy, providing pre-clinical evidence for the use of statins in patients. Ultimately, this will advance the use of statins to the oncology clinic, moving one step closer to employing a cheap, safe, and effective family of cholesterol-lowering drugs to treat aggressive forms of cancer."
Competitiondate
201912
Approvedterm2
1 yr 0 mth
Pinamesdelim
MacDonald, Kate
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~